home / stock / nwphf / nwphf quote
Last: | $2.80 |
---|---|
Change Percent: | 0.0% |
Open: | $2.8 |
Close: | $2.80 |
High: | $2.8 |
Low: | $2.8 |
Volume: | 2,000 |
Last Trade Date Time: | 06/08/2021 04:41:54 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.8 | $2.8 | $2.8 | $2.8 | $2.8 | 2,000 | 06-08-2021 |
$2.79 | $2.79 | $2.79 | $2.79 | $2.79 | 2,000 | 06-01-2021 |
$2.8 | $2.78 | $2.8 | $2.8 | $2.78 | 6,000 | 05-31-2021 |
$2.8 | $2.78 | $2.8 | $2.8 | $2.78 | 6,000 | 05-28-2021 |
$2.8 | $2.8 | $2.8 | $2.8 | $2.8 | 1,000 | 04-12-2021 |
$3 | $3 | $3 | $3 | $3 | 1,000 | 03-26-2021 |
$3 | $3 | $3 | $3 | $3 | 8,533 | 03-15-2021 |
$2.47 | $2.469995 | $2.47 | $2.47 | $2.47 | 30,000 | 12-08-2020 |
$2.26 | $2.26 | $2.26 | $2.26 | $2.26 | 110 | 12-04-2020 |
$1.9629 | $1.96289 | $1.9629 | $1.9629 | $1.9629 | 20,092 | 11-11-2020 |
$1.9 | $1.9 | $1.9 | $1.9 | $1.9 | 900 | 10-29-2020 |
$1.9 | $1.9 | $1.9 | $1.9 | $1.9 | 220 | 10-27-2020 |
$2.55 | $2.55 | $2.55 | $2.55 | $2.55 | 200 | 10-21-2020 |
$2.55 | $2.55 | $2.55 | $2.55 | $2.55 | 1,076 | 10-15-2020 |
$2.02 | $2.02 | $2.02 | $2.02 | $2.02 | 1,125 | 10-12-2020 |
$2.55 | $2.75 | $2.55 | $2.75 | $2.55 | 600 | 08-26-2020 |
$1.81 | $1.83 | $1.81 | $1.83 | $1.81 | 2,000 | 06-26-2020 |
$1.83 | $1.83 | $1.83 | $1.83 | $1.83 | 500 | 06-25-2020 |
$1.85 | $1.85 | $1.85 | $1.85 | $1.85 | 329 | 06-08-2020 |
$1.85 | $1.85 | $1.85 | $1.85 | $1.85 | 948 | 06-04-2020 |
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
OTCMKTS Market:
Data from study 014/015, a phase II trial evaluating evenamide as add-on therapy for patients with treatment-resistant schizophrenia (TRS) for up to one year Presentation of study design for potentially pivotal phase III trial for TRS patients Information on potentially pivotal st...
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...